Prelude Therapeutics Inc (PRLD) stock forecast and price target
Price $3.45 · data as of November 13, 2026
12-month price target
Average target$9.20
Upside / downside+166.7%
Analysts5
ConsensusNone
Low $6.00Average $9.20High $12.00
Gold marker: average target · white marker: today’s price ($3.45)
Analyst ratings
Strong buy 2Buy 3Hold 0Sell 0Strong sell 0
Earnings and revenue estimates
| Period | EPS estimate | EPS growth | Revenue estimate |
|---|---|---|---|
| Current fiscal year ends December 31, 2026 | $-0.57 | +56.1% | $39M |
| Next fiscal year ends December 31, 2027 | $-0.58 | −2.4% | $36M |
| Quarter after ends December 31, 2026 | $-0.15 | +24.1% | $4M |
Consensus of the analysts covering Prelude Therapeutics, updated daily.
Frequently asked questions
What is the Prelude Therapeutics stock price target?
The average 12-month target from 5 analysts is $9.20, 166.7% above the current price of $3.45 Targets range from $6.00 to $12.00.
Is Prelude Therapeutics a buy according to analysts?
The consensus rating is “None” (2 strong buy, 3 buy). Ratings are opinions, not guarantees; this is not investment advice.
How much is Prelude Therapeutics expected to earn?
Analysts expect EPS of $-0.57 for the fiscal year ending December 31, 2026 and $-0.58 the year after.
Analyst consensus estimates and price targets, updated daily. Forecasts can be wrong; this is information, not investment advice.